IntraLase maintains outperform by RBC

RBC Capital Markets analyst Phil Nalbone kept IntraLase Corp. at an outperform, speculative risk rating and $25 price target after the company introduced its IntraLase FS laser application for corneal transplant at a conference in London. Known as IntraLase Enabled Keratoplasty (IEK), the laser will cost $425,000 with upgrades to existing IntraLASIK systems costing $50,000. Shares of the Irvine, Calif.-based vision laser products company were up 67 cents, or 3.55%, at $19.56. (Nasdaq: ILSE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.